One Of The Cyclos Is A 1,2-thiazine (e.g.,1,2-benzothiazines, Etc.) Patents (Class 514/226.5)
-
Publication number: 20120213855Abstract: This disclosure relates to dosage forms (e.g., solid dosage forms) comprising a drug-containing emulsion, a drug-containing microemulsion, a self-emulsifying oil composition, or a self-microemulsifying oil composition, wherein each comprises a weakly ionizable drug and a pH modifier. Also provided are pharmaceutical dosage forms (e.g., solid dosage forms) and methods of preparing the same.Type: ApplicationFiled: February 17, 2011Publication date: August 23, 2012Applicant: CIMA LABS INC.Inventors: Vikas AGARWAL, Sami M. NAZZAL
-
Publication number: 20120214794Abstract: This invention provides compounds of formula I-A or I-B: wherein HY, G1, G2, R2, R12, W1, W2, n, and Ring A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.Type: ApplicationFiled: October 13, 2011Publication date: August 23, 2012Applicant: Millennium Pharmaceuticals, Inc.Inventors: Brian S. Freeze, Masaaki Hirose, Hong Myung Lee, Todd B. Sells, Zhan Shi, Leo R. Takaoka, Stepan Vyskocil, Tianlin Xu
-
Publication number: 20120213869Abstract: A pain relieving composition that includes an anesthetic in the range of 0.5%-7.0% by weight (“w/w”), an anti-inflammatory agent in the range of 1.0%-11.0% w/w, a moisturizing agent in the range of 0.5%-12.0% w/w, a humescent in the range of 0.5%-13.0% w/w, a penetration enhancing agent in the range of 0.5%-7.0%, and a carrier solvent in the range of 40.0%-97.0% w/w to be used before and/or after procedures which cause damage to human skin.Type: ApplicationFiled: February 23, 2011Publication date: August 23, 2012Applicant: MISS SMARTY PANTS ENTERPRISES, INC.Inventor: Edna Ma
-
Publication number: 20120202694Abstract: The present invention relates to methods for producing particles of a biologically active material using dry milling processes as well as compositions comprising such materials, medicaments produced using said biologically active materials in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of said biologically active materials administered by way of said medicaments.Type: ApplicationFiled: April 23, 2010Publication date: August 9, 2012Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H William Bosch
-
Publication number: 20120178728Abstract: The use of copolymers obtained by free-radical polymerization of a mixture of i) 30 to 80% by weight of N-vinyllactam, ii) 10 to 50% by weight of vinyl acetate, and iii) 10 to 50% by weight of a polyether, with the proviso that the total of components i), ii) and iii) equals 100% by weight, as solubilizers for slightly water-soluble substances.Type: ApplicationFiled: March 21, 2012Publication date: July 12, 2012Applicant: BASF SEInventors: Nathalie Bouillo, Marianna Pierobon, Ralf Widmaier, Rainer Dobrawa, Kathrin Meyer-Böhm, Ronald Frans Maria Lange
-
Publication number: 20120168335Abstract: The invention provides pharmaceutical compositions comprising a therapeutically effective amount of meloxicam, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical compositions are in the form of a fast disintegrating dosage form suitable for releasing meloxicam rapidly in the oral cavity. Also provided are processes for preparing a pharmaceutical composition of the invention. Further provided are methods of treating arthritis or pain in a subject in need thereof, the method comprising orally administering to the subject a therapeutically effective amount of a pharmaceutical composition according to the invention.Type: ApplicationFiled: August 31, 2010Publication date: July 5, 2012Inventors: David Allen Burns, Grregory Edward Neal
-
Patent number: 8211887Abstract: Disclosed herein is a preparation for topically delivering and localizing therapeutic agents, comprising: a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; and a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Further disclosed is an associated method of topically delivering and localizing therapeutic agents, comprising the steps of: using a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; in combination with using a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Also disclosed are various courses of treatment, which comprise applying the various disclosed combinations of agents to the patient's skin.Type: GrantFiled: June 1, 2005Date of Patent: July 3, 2012Inventors: David M. Richlin, George R. Doherty
-
Publication number: 20120165323Abstract: The present invention relates to a method for improving the dissolution profile of a biologically active material comprising the steps of dry milling a solid biologically active material and a millable grinding matrix in a mill comprising a plurality of milling bodies, for a time period sufficient to produce particles of the biologically active material dispersed in an at least partially milled grinding material.Type: ApplicationFiled: April 23, 2010Publication date: June 28, 2012Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H William Bosch, Matt Callahan
-
Publication number: 20120164221Abstract: The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy, or rhabdomyolysis.Type: ApplicationFiled: October 27, 2011Publication date: June 28, 2012Inventors: David J. Bova, Josephine Dunne
-
Publication number: 20120149692Abstract: The invention is directed to novel crystalline forms of meloxicam. These novel crystalline forms of meloxicam have improved bioavailability, an enhanced rate of dissolution and shorter time to Cmax in blood, as compared to pure meloxicam.Type: ApplicationFiled: February 17, 2012Publication date: June 14, 2012Applicant: THAR PHARMACEUTICALSInventors: Mazen Hanna, Ning Shan, Miranda L. Cheney, David R. Weyna
-
Publication number: 20120141467Abstract: Provided herein is a method for treating a tracheo-bronchial-alveolar tract disease in a subject in need thereof, the method comprising the step of administering to a subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of ascorbate or a derivative thereof. Also provided is a method for treating non-Hodgkin's lymphoma in a subject in need thereof, the method comprising the step of administering to the subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of ascorbate or a derivative thereof.Type: ApplicationFiled: December 3, 2010Publication date: June 7, 2012Inventor: Daniel J. Schneider
-
Publication number: 20120141548Abstract: The present invention relates to methods for producing particles of meloxicam using dry milling processes as well as compositions comprising meloxicam, medicaments produced using meloxicam in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of meloxicam administered by way of said medicaments.Type: ApplicationFiled: April 23, 2010Publication date: June 7, 2012Applicant: FUNDACIONUNIVERSIDAD DEL NORTEInventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H William Bosvch
-
Patent number: 8193209Abstract: Disclosed is a pharmaceutical composition, comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of meloxicam and/or at least one a pharmaceutically acceptable salt thereof and a dose oxycodone and/or at least one a pharmaceutically acceptable salt thereof, the two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising administering to the patient a an oral dosage form comprising two analgesic compounds consisting of meloxicam and/or at least one a pharmaceutically acceptable salt thereof and oxycodone and/or at least one a pharmaceutically acceptable salt thereof, the two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient.Type: GrantFiled: January 25, 2002Date of Patent: June 5, 2012Assignee: Purdue Pharma L.P.Inventors: Ronald M. Burch, Richard S. Sackler, Paul D. Goldenheim
-
Publication number: 20120129845Abstract: This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives according to generic Formulae I-IV: wherein, variables R, X, Y1, Y2, Y2?, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions comprising compounds of Formulae I-IV and at least one carrier, diluent or excipient.Type: ApplicationFiled: January 26, 2012Publication date: May 24, 2012Inventors: Nolan James Dewdney, Rama K. Kondru, Bradley E. Loe, Yan Lou, Joel McIntosh, Timothy D. Owens, Michael Soth
-
Patent number: 8183236Abstract: Pharmacophore models to be used in drug design and discovery are provided. An in silico protocol and in vitro assays are presented. Compounds and their pharmaceutically acceptable salts with HIV-1 integrase inhibitory and anti-HIV activity and use thereof in the treatment of HIV/AIDS and related infections either alone or in combination with all the known antiretroviral therapeutics are described.Type: GrantFiled: April 14, 2008Date of Patent: May 22, 2012Assignee: University of Southern CaliforniaInventors: Nouri Neamati, Raveendra S. Dayam
-
Publication number: 20120121567Abstract: An ophthalmic solution containing riboflavin and at least a compound chosen in the group composed of essential and conditionally essential amino acids, coenzyme Q, L-proline, glycine, lysine hydrochloride, L-leucine, L-arginine and compounds intended to stimulate the production of metalloproteinase MMP9 for the protection of internal structures of the eyeball against UV-A rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique.Type: ApplicationFiled: July 23, 2010Publication date: May 17, 2012Inventors: Salvatore Troisi, Antonio Del Prete, Ciro Caruso
-
Publication number: 20120114740Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.Type: ApplicationFiled: October 27, 2011Publication date: May 10, 2012Applicant: PACIRA PHARMACEUTICALS, INCInventors: Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou
-
Publication number: 20120108553Abstract: The present invention is directed to nicotinamide, nicotinamide derivatives and prostaglandin mimetics, alone or in combination with an NSAID, and their use in treating pain, inflammation, and/or gastrointestinal toxicty,Type: ApplicationFiled: May 3, 2011Publication date: May 3, 2012Applicant: Cortria CorporationInventor: Alexander KRANTZ
-
Patent number: 8168629Abstract: Disclosed is a pharmaceutical composition, comprising a combination of a dose of meloxicam or a pharmaceutically acceptable salt thereof and a dose of tramadol or a pharmaceutically acceptable salt thereof, the combination in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising administering to the patient a combination of a dose of meloxicam or a pharmaceutically acceptable salt thereof and a dose of tramadol or a pharmaceutically acceptable salt thereof such that the dosing interval of the meloxicam overlaps with the dosing interval of the tramadol, the combination in an amount sufficient to provide an analgesic effect in a human patient.Type: GrantFiled: July 10, 2007Date of Patent: May 1, 2012Assignee: Purdue Pharma L.P.Inventors: Ronald M. Burch, Paul D. Goldenheim, Richard S. Sackler
-
Publication number: 20120094932Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6 and R8 are each independently a member selected from the group consisting of H, C1-6 alkyl and OH; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites and prodrugs thereof.Type: ApplicationFiled: December 21, 2011Publication date: April 19, 2012Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Publication number: 20120093938Abstract: The compositions of the present invention comprise a therapeutically effective amount of particles consisting of diphenhydramine or pharmaceutically acceptable salts thereof, optionally in combination with another drug such as pseudoephedrine, or phenylephrine and hydrocodone, in combination with rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol and/or a saccharide. These compositions are useful in treating the symptoms of one or more diseases or conditions in which diphenhydramine (alone or in combination with one or two other drugs) is a therapeutically effective, e.g. allergic rhinitis, sinusitis, upper respiratory tract infections, motion sickness, Parkinson's disease, insomnia, the common cold, and nighttime pain management, particularly for subjects or patients with dysphagia, and people ‘on the move’.Type: ApplicationFiled: July 14, 2011Publication date: April 19, 2012Applicant: EURAND INC.Inventors: Gopi M. VENKATESH, Jin-Wang LAI, Phillip PERCEL, Craig KRAMER
-
Publication number: 20120087959Abstract: The present invention provides a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more drugs, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or its derivatives or its salts.Type: ApplicationFiled: June 18, 2010Publication date: April 12, 2012Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITEDInventors: Ajay Jaysingh Khopade, N Arulsudar, Subhas Balaram Bhowmick
-
Publication number: 20120083447Abstract: Methods of treating hypertension, pain, and resuscitative hemorrhagic shock using an adrenergic agent, like centhaquin, are disclosed. The methods treat mammals, including humans.Type: ApplicationFiled: April 29, 2010Publication date: April 5, 2012Applicant: MIDWESTERN UNIVERSITYInventor: Anil Gulati
-
Publication number: 20120070467Abstract: The present invention includes and provides a method of delivering a medicament to an eye of a subject in need thereof a solution, the method comprising: (a) providing droplets containing the medicament with a specified average size and average initial ejecting velocity; and (b) delivering the medicament to the eye, where the droplets deliver a percentage of the ejected mass of the droplets to the eye.Type: ApplicationFiled: July 15, 2011Publication date: March 22, 2012Applicant: Corinthian Ophthalmic, Inc.Inventors: Bernard L. Ballou, JR., Mark Packer, Russell John Mumper, Tsontcho Inachulev
-
Patent number: 8129370Abstract: The invention relates to the use of lornoxicam or analogues thereof which inhibit cyclo-oxygenase 1 and cyclo-oxygenase 2 (COX 1 and COX 2), cannot penetrate the blood-brain barrier under physiological conditions, and reduce the prostaglandin E2-induced induction of the amyloid-precursor-protein (APP), for producing a pharmaceutical composition for the treatment or prevention of Alzheimer's disease or arteriosclerosis.Type: GrantFiled: May 27, 2004Date of Patent: March 6, 2012Assignee: Dritte PatentPortfolio Beteiligungsgesellschaft MBH & Co. KGInventors: Dieter Binder, Eva Binder, legal representative
-
Publication number: 20120054920Abstract: The present invention provides a composition comprising an amphiphile and an active ingredient whose solubility in water at 20° C. is not more than 10 g/L. Likewise provided is an amphiphile comprising a hyperbranched polycarbonate which is joined to at least one linear or comb-type polymer, a process for preparing the amphiphile, and the use of the amphiphile in compositions comprising an active ingredient whose solubility in water at 20° C. is not more than 10 g/L.Type: ApplicationFiled: May 4, 2010Publication date: March 1, 2012Applicant: BASF SEInventors: Holger Tuerk, Monika Haberecht, Michael Ishaque, Hiroe Yamada, Daniel Schoenfelder, Bernd Bruchmann
-
Publication number: 20120052118Abstract: The present invention provides an apparatus and process for making softgel capsules having incorporated therein other solid dosage forms selected from the group consisting of pellets, smaller capsules, smaller tablets, sustained release solid dosage forms, immediate release solid dosage forms, extended release solid dosage forms and zero order release solid dosage forms, said apparatus comprising: (a) two spreader boxes; (b) two casting drums; (c) a pair of rotary dies having means for suction; (d) a liquid fill system; (e) a wedge for heating gelatine ribbons and feeding said fill; and (f) two lateral dispensing devices said lateral dispensing devices including hoppers having said solid dosage forms, channelguides for transporting said solid dosage forms and a grasping claw for dispensing said solid dosage form into the softgel pocket formed in the rotary dies.Type: ApplicationFiled: July 18, 2011Publication date: March 1, 2012Inventors: Carlos Salazar Altamar, Gustavo Anaya, Braulio Teran, Newman Aguas Navarro, Willmer Herrera
-
Patent number: 8124603Abstract: The invention is directed to novel crystalline forms of meloxicam. These novel crystalline forms of meloxicam have improved bioavailability, an enhanced rate of dissolution and shorter time to Cmax in blood, as compared to pure meloxicam.Type: GrantFiled: January 22, 2009Date of Patent: February 28, 2012Assignee: Thar PharmaceuticalsInventors: Mazen Hanna, Ning Shan, Miranda L. Cheney, David R. Weyna
-
Publication number: 20120035143Abstract: The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.Type: ApplicationFiled: February 18, 2010Publication date: February 9, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Peter Nickolaus, Rolf Goeggel, Daniel Peter
-
Publication number: 20120035162Abstract: The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid to yield high-purity meloxicam.Type: ApplicationFiled: October 12, 2011Publication date: February 9, 2012Inventors: Tibor MEZEI, Gyula Simig, Enikó Molnár, Gyula Lukács, Márta Porcs-Makkay, Balázs Volk, Valéria Hofmanné Fekete, Kálmán Nagy, Norbert Mesterházy, György Krasznai, Györgyi Vereczkeyné Donáth, Gyuláné Körtvélyessy, Éva Pécsi
-
Publication number: 20120028932Abstract: The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryl and wherein R1 and R2 have the meanings given in claim 1, contain at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.Type: ApplicationFiled: February 18, 2010Publication date: February 2, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Peter NICKOLAUS, Rolf GOEGGEL, Daniel PETER
-
Publication number: 20120024743Abstract: The present invention relates to semisolid transdermal pharmaceutical preparation having enhanced stability and bioavailability, wherein the particles are coated by a volatile silicon oil component and the thus obtained suspension is dispersed in a gel or cream base.Type: ApplicationFiled: February 5, 2010Publication date: February 2, 2012Applicant: EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAGInventors: Endre Mikulasik, Patrik Fazekas
-
Publication number: 20120027879Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: August 3, 2011Publication date: February 2, 2012Inventor: Harry A. DUGGER, III
-
Patent number: 8097616Abstract: The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium sait monohydrate is produced. Said sait is subsequently treated with mineral or organic acid to yield high-purity meloxicam.Type: GrantFiled: December 16, 2005Date of Patent: January 17, 2012Assignee: Egis Gyogyszergyar Nyilvanosan Mukodo ReszvenytarsasagInventors: Tibor Mezei, Gyula Simig, Enikó Molnár, Gyula Lukács, Márta Porcs-Makkay, Balázs Volk, Valéria Hofmanné Fekete, Kálmán Nagy, Norbert Mesterházy, György Krasznai, Györgyi Vereczkeyné Donáth, Gyuláné Körtvélyessy, Éva Pécsi
-
Publication number: 20110319399Abstract: An external preparation containing the following components (A) and (B): (A) a non-steroidal analgesic/anti-inflammatory agent, and (B) an organic amine. The external preparation of the present invention has improved skin permeation and excellent stability of a non-steroidal analgesic/anti-inflammatory agent in the external preparation. The external preparation of the present invention also has excellent appearance.Type: ApplicationFiled: March 11, 2010Publication date: December 29, 2011Applicant: KOWA CO., LTD.Inventors: Seiji Miura, Tsutomu Awamura, Yuhiro Yamazaki, Hironari Fujii
-
Publication number: 20110319326Abstract: The object of the present invention is benzothiazine derivatives having the capability of inhibiting 11?-HSD1 not only at an enzymatic level but also at a cell level. The compounds of the present invention are of general formula (I). Wherein notably R1 represents a hydrogen or OR1 represents an ester or an ether. R2 represents a naphthyl or a 1, 2, 3, 4-tetrahydro-naphthalene or a biphenyl or phenyl pyridine or a substituted phenyl. R3 represents a methyl or ethyl; R4 and R?4 represent a hydrogen.Type: ApplicationFiled: March 2, 2010Publication date: December 29, 2011Applicant: PIERRE FABRE MEDICAMENTInventors: Michel Perez, Marie Lamothe, Didier Junquero, Yves Rival
-
Publication number: 20110301131Abstract: The invention discloses an implant suitable for delivery of at least one drug, the implant comprising a fibrillar collagen matrix having, as measured in Example 1, a viscosity of greater than 100 mPas, optionally greater than 103 mPas, further optionally greater than 106 mPas, still further optionally greater than 109 mPas when a collagen dispersion formed from 140 mg of the fibrillar collagen matrix is dispersed in 25 ml of 2 mM HCl at a pH of less than 3.5 and at a temperature of 30.0+/?0.5° C.Type: ApplicationFiled: November 6, 2009Publication date: December 8, 2011Inventors: Joan Fitzpatrick, David Prior
-
Publication number: 20110293721Abstract: This invention relates to matrix patches for the topical (i.e., transdermal) delivery of piroxicam and methods for the treatment of acute and chronic pain and inflammation therewith, particularly pain and inflammation caused by sports injuries or other muscle aches or injuries requiring the application of analgesic and/or anti-inflammation medication, in this instance, piroxicam.Type: ApplicationFiled: May 25, 2011Publication date: December 1, 2011Inventors: Changjin Wang, Eric Y. Sheu, Nancy Vuong
-
Publication number: 20110280916Abstract: Stable formulations of an active pharmaceutical agent suitable for oral spray administration for absorption by the oral mucosa and related methods of preparation and administration of active pharmaceutical agent formulations are provided. Preferred embodiments of the invention provide formulations comprising an active pharmaceutical agent, a solvent, a buffer, and a viscosity modifying agent, wherein when a unit dose volume of about 25 to 400 mcL of the oral spray composition is sprayed, the spray has a median particle size diameter of about 40 to about 100 microns.Type: ApplicationFiled: July 22, 2011Publication date: November 17, 2011Inventors: Frank E. Blondino, Howard Malitz
-
Publication number: 20110275618Abstract: The invention relates to a solid tablet that is directly-compressed of powder, comprising meloxicam and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the active ingredient, meloxicam.Type: ApplicationFiled: April 26, 2011Publication date: November 10, 2011Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Martin A. FOLGER, Stefan LEHNER, Horst SCHMITT
-
Publication number: 20110275617Abstract: The present invention provides an ophthalmic composition comprising a hyperbranched polymer. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polymer increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such as polysorbate, hydroxypropyl methyl cellulose or hydroxyethyl cellulose, and beta-blockers, such as carteolol, levobunolol, betaxolol, metipranolol, timolol or propranolol.Type: ApplicationFiled: May 5, 2010Publication date: November 10, 2011Inventors: Jun INOUE, Tapan Shah
-
Publication number: 20110269715Abstract: The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, R1 and R2 are as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound.Type: ApplicationFiled: June 2, 2011Publication date: November 3, 2011Inventors: June Chen, Simon N. Pettit, Hans G. Fliri
-
Publication number: 20110269723Abstract: The invention relates to novel spill resistant formulations comprising either a weak base or a weak acid as the pharmaceutical ingredient, a liquid base, a clay and a water soluble cellulose ether. The clay and cellulose ether allow for a broader pH range into which the pharmaceutically active agent may be dispersed or dissolved, and therefore allows for easier preparation and formulation of the pharmaceutical composition.Type: ApplicationFiled: July 12, 2011Publication date: November 3, 2011Applicant: Taro Pharmaceuticals U.S.A., Inc.Inventors: Satish ASOTRA, Xiaoli Wang, Zoltan Bodor
-
Publication number: 20110269724Abstract: The present invention is directed to nicotinamide, nicotinamide derivatives and prostaglandin mimetics, alone or in combination with an NSAID, and their use in treating pain, inflammation, and/or gastrointestinal toxicty,Type: ApplicationFiled: May 3, 2011Publication date: November 3, 2011Applicant: Cortria CorporationInventor: Alexander KRANTZ
-
Publication number: 20110263545Abstract: The present invention provides hepatoprotectant acetaminophen mutual prodrugs, which have an acetaminophen moiety covalently linked to a second moiety that may act as a hepatoprotectant against acetaminophen hepatotoxicity. Additionally, acetaminophen mutual prodrugs may have improved water solubility which may provide better suitability for parenteral and other dosage forms relative to administration of acetaminophen. Also provided are methods of treating a disease or condition that is responsive to acetaminophen (such as fever, pain and ischemic injury) using hepatoprotectant acetaminophen mutual prodrugs, as well as kits and unit dosages.Type: ApplicationFiled: May 20, 2009Publication date: October 27, 2011Inventors: Naweed Muhammad, Keith R. Bley, Jeffrey Tobias
-
Publication number: 20110263580Abstract: This invention relates to a method for treating or preventing diseases associated with the deposition of ?-amyloid peptide in the brain, such as Alzheimer's disease, said method involving administration of a gamma-secretase inhibitor in an intermittent dosing regime to a patient in need thereof.Type: ApplicationFiled: December 4, 2009Publication date: October 27, 2011Inventor: Thomas Miller
-
Publication number: 20110245172Abstract: The present invention relates to biocompatible oligomer-polymer compositions for the in situ formation of implants, wherein the implants release a bioactive agent, a metabolite, or a prodrug thereof, at a controlled rate. The sustained release delivery system includes a flowable composition containing a bioactive agent, a metabolite, or a prodrug thereof, and an implant containing a bioactive agent, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, a biocompatible end-capped oligomeric liquid, and a bioactive agent, a metabolite, or a prodrug thereof.Type: ApplicationFiled: June 3, 2009Publication date: October 6, 2011Applicant: Tolmar Therapeutics, Inc.Inventor: Richard L. Norton
-
Publication number: 20110237563Abstract: The present invention related to the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with critical buccal condition, leading to difficulties in swallowing oral medicine forms and thus difficulties in treating said illnesses. Particularly, the present invention discloses the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with dysphagia and/or odynophagia and/or aspiration risk. Another aspect of the present invention is the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for the treatment of dysphagia and/or odynophagia and/or aspiration risk.Type: ApplicationFiled: March 23, 2010Publication date: September 29, 2011Inventor: Dominique Costantini
-
Publication number: 20110224196Abstract: This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from obstructive sleep apnea syndrome (OSAS). Treatment of OSAS is effected by administering a carbonic anhydrase inhibitor to the patient in combination with at least one additional active agent. Examples of additional active agents include modafinil, eszopiclone, zolpidem, zaleplon, and phentermine.Type: ApplicationFiled: January 7, 2011Publication date: September 15, 2011Applicant: Vivus, Inc.Inventors: Leland F. Wilson, Peter Tam, Thomas Najarian, Charles H. Bowden
-
Publication number: 20110217341Abstract: The present invention relates to a method for preparing microspheres and microspheres prepared thereby, more particularly to a method for preparing a polymeric microsphere, including preparing an emulsion including a polymer compound, a drug, a water-insoluble organic solvent and a dispersion solvent and adding to the prepared emulsion a base or an acid to remove the water-insoluble organic solvent from the emulsion, a polymeric microsphere prepared thereby, and a composition for drug delivery including the microsphere. According to the present invention, a drug-containing polymer microsphere may be prepared quickly and simply without the solvent evaporation or solvent extraction process, thereby reducing water consumption and minimizing wastewater generation.Type: ApplicationFiled: May 12, 2011Publication date: September 8, 2011Applicants: EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION, SK CHEMICALS CO., LTD.Inventor: Hong Kee SAH